Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Aug 7 2025 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Industry News Industry Read More Aug 7 2025 | Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Industry News Industry Read More Aug 3 2025 | HFSA President's Update: August 2025 HFSA News President's Updates Read More Jul 19 2025 | Gene Therapy in Heart Failure: A Breakthrough for Danon Disease and Beyond HFSA News Podcasts Read More Jul 14 2025 | Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 10 Page 11 Page 12 Page 13 Current page 14 Page 15 Page 16 Page 17 Page 18 … Next page Next › Last page Last »
Aug 7 2025 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Industry News Industry Read More
Aug 7 2025 | Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Industry News Industry Read More
Jul 19 2025 | Gene Therapy in Heart Failure: A Breakthrough for Danon Disease and Beyond HFSA News Podcasts Read More
Jul 14 2025 | Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Industry News In The News Industry Read More
